Tenon Medical, Inc.

Tenon Medical, Inc. announced its 2026 Annual Meeting of Stockholders, to be held virtually on July 23, 2026. Key proposals include an amendment to its Certificate of Incorporation to effect a reverse stock split at a ratio between 1:2 and 1:35. Shareholders will also vote on approving the issuance of shares related to a March 2026 debt financing and future financings to comply with Nasdaq listing rules, alongside the election of seven directors and the ratification of the company's auditor.

Tenon Medical, Inc. has filed an S-1 registration statement for a public offering of up to 1,812,987 shares of common stock, along with common stock purchase warrants to acquire up to 6,975,584 shares. Additionally, the company is offering pre-funded warrants to purchase up to 4,000,000 shares. The assumed combined public offering price is $0.6021 per share and accompanying Common Warrants, with proceeds intended for commercial expansion, research and development, inventory, and general corporate purposes. The offering will result in immediate dilution for existing shareholders.

Tenon Medical, Inc. announced its 2026 Executive Compensation Plan, effective March 1, 2026, which includes a 5% increase in annual base salaries for its CEO, CFO, and COO. The plan also revised annual bonus opportunities and introduced a second bonus for these executives based on milestone achievements. Additionally, the company extended Executive Chairman Richard Ferrari's consulting agreement for another year, maintaining his compensation at $45,000 per quarter.

Tenon Medical, Inc.'s Board of Directors approved Amendment No. 1 to the Company's Bylaws, effective June 10, 2026. The amendment revises the quorum requirement for stockholder meetings from a majority to not less than 33 1/3% of outstanding shares entitled to vote, in accordance with Nasdaq Listing Rule 5620. Additionally, it modifies voting provisions to allow a majority of votes present at a meeting (instead of a majority of all outstanding shares) to determine if voting should be by written ballot and conducted by inspectors.

Tenon Medical, Inc. received a notice from Nasdaq on May 21, 2026, stating non-compliance with the minimum stockholders' equity requirement for continued listing. The company reported stockholders' equity of $1,895,000 as of March 31, 2026, which is below Nasdaq's required $2,500,000. Tenon Medical has until July 6, 2026, to submit a plan to regain compliance, with a potential extension of up to 180 days if the plan is accepted. The notice does not immediately affect the company's stock listing or trading.

Tenon Medical, Inc. reported a significant increase in revenue and gross profit for the first quarter of 2026, with revenue rising 89.9% to $1.38 million and gross profit surging 192.6% to $0.95 million. The company also narrowed its net loss to $3.48 million from $3.62 million in the prior year period. However, the company disclosed substantial doubt about its ability to continue as a going concern and received a Nasdaq notice for failing to meet the minimum bid price requirement. Additionally, Tenon Medical issued $4.3 million in gross proceeds from convertible promissory notes to address liquidity needs.

Tenon Medical, Inc. reported strong financial results for the first quarter ended March 31, 2026, with revenue increasing by 90% to $1.4 million and gross profit surging by 193% to $0.9 million. The company also significantly improved its gross margin to 68.5% and reduced its net loss year-over-year. Additionally, Tenon Medical closed a $4.3 million private placement to support commercial expansion and product development, while also strengthening its intellectual property portfolio and expanding its training and sales presence.